

# PrIOMiC-OncoPoint symposium 2023 – final program

3-4 May 2023 – Het Pand (Gent)

<https://www.crig.ugent.be/en/events/priomic-oncopoint-symposium-2023>

## Wednesday 3 May

(topics: precision oncology, cancer modeling, multidisciplinary cancer research)

---

*(8:30 – 10:30 restricted satellite symposium, only for PrIOMiC promoters & international partners)*

10:30 – 11:00 registration & welcome coffee

11:00 – 11:10 **introduction of the joined PrIOMiC network and OncoPoint meeting**  
 Prof. Katleen De Preter (CRIG chairperson)  
 Prof. Guido Van Huylbroeck (UGent director for internationalisation)

11:10 – 12:40 **session 1**

- **11:10 international PrIOMiC partner**  
**Prof. Alex Wyatt** (University of British Columbia) – ‘Genomic heterogeneity in treatment-naive metastatic prostate cancer’
- **11:35 international PrIOMiC partner**  
**Prof. Kyra Campbell** (University of Sheffield) – ‘Harnessing the power of the fruit fly to tackle cancer metastasis’
- **12:00 storm session A - short pitches of selected abstracts**

12:40 – 13:10 **poster session**

13:10 – 13:50 **lunch, sponsor booths & poster session (continued)**

13:50 – 15:20 **session 2**

- **13:50 PrIOMiC partnership**  
**Prof. Henrik Grönberg** (Karolinska Institute) – ‘Towards clinical relevant insight during the ProBio trial, a randomized, outcome-adaptive, biomarker-driven platform trial’  
**Dr. Johan Lindberg** (Karolinska Institute) – ‘The ProBio liquid biopsy infrastructure, from research to clinical routine’  
**Dr. Bram De Laere** (UGent, Karolinska Institute, CRIG) – ‘Setting up a liquid biopsy biobanking infrastructure in context of the ProBio trial’

- **14:40 selected abstract presentation**  
**Louise de Schaetzen** (UGent, CRIG) – ‘Identification of transcriptomic signature characterizing evolution from primary to metastatic prostate cancer’
- **14:55 selected abstract presentation**  
**Annelien Morlion** (UGent, CRIG) – ‘Pan-cancer blood plasma cfRNA profiles reveal cancer type and patient-specific changes’
- **15:10 meet our ‘ERC Consolidator Grant 2023’ laureate**  
**Prof. An Ghysels** (UGent, CRIG) – ‘PASTIME: understanding the role of time in biomedical processes (& applications in oncology)’

15:20 – 15:50 **coffee break, sponsor booths & poster viewing**

15:50 – 17:20 **session 3**

- **15:50 PrIOMiC partnership**  
**Prof. Roderick Beijersbergen** (Netherlands Cancer Institute) – ‘Diving deep: large scale functional genomic screening for complex and dynamic phenotypes’  
**Prof. Pieter Mestdagh** (UGent, CRIG) – ‘Identifying non coding RNA regulators of tumor-mediated T-cell suppression using CRISPRi screens’
- **16:25 international PrIOMiC partner**  
**Prof. Frédéric Saltel** (BRIC, Bordeaux University) – ‘From cell to tissue: proteomic profiling to reach precision medicine in liver tumors’
- **16:50 selected abstract presentation**  
**Kathleen Schoofs** (VIB-UGent, CRIG) – ‘Therapy response monitoring in patients with esophageal adenocarcinoma using cell-free DNA methylation profiling’
- **17:05 selected abstract presentation**  
**Dr. Dorien Clarisse** (VIB-UGent, CRIG) –  
‘It takes two: glucocorticoid and mineralocorticoid receptor crosstalk boosts glucocorticoid-induced killing of multiple myeloma cells’

17:20 – 17:30 **closing remarks**

17:30 – 18:00 **session 4: ‘meet the international partners’** + opportunity to have a drink

*format:*

- *meet-the-expert session per international institute/partner that presented today – at separate round tables to allow face-to-face interaction and discussions in small groups (in the reception area, with opportunity to have a drink)*
- *participants can join the tables spontaneously, and visit several tables during the session to actively interact with the partners or to follow the ongoing discussions.*

18:00 – 18:30 **reception (continued)**

## Thursday 4 May

(topic plenary sessions: immuno-oncology + parallel sessions on

(A) fundamental/translational cancer research & (B) clinical/psychosocial cancer research)

---

8:30 – 9:00 registration

9:00 – 9:05 **introduction**

9:05 – 10:30 **session 5**

- **9:05 PrIOMiC partnership**  
**Prof. Steve Pascolo** (University Hospital of Zurich) – ‘Chemically synthesised RNA for anticancer vaccination and therapies’  
**Prof. Karim Vermaelen** (U(Z)Gent, CRIG) – ‘mRNA technology at the core of ongoing cancer immunotherapy developments at Ghent University (Hospital)’
- **9:55 storm session B - short pitches of selected abstracts**

10:30 – 11:00 **coffee break, sponsor booths & poster viewing**

11:00 – 12:20 **session 6**

- **11:00 international PrIOMiC partner**  
**Prof. Emma Morris** (University College London) – ‘TCR gene modified T cells for cancer and autoimmunity’
- **11:25 selected abstract presentation**  
**Stijn De Munter** (UGent, CRIG) – ‘Optimizing CD70 specific VHH based CARs for the treatment of solid and liquid malignancies’
- **11:40 selected abstract presentation**  
**Hanne Verschuere** (VIB-UGent, CRIG) – ‘Enhancing anti-tumor immunity through intratumoral combination therapy with amphiphilic conjugates of oxaliplatin and imidazoquinoline TLR7 agonist’
- **11:55 storm session C - short pitches of selected abstracts**

12:20 – 12:50 **poster session**

12:50 – 13:40 **lunch, sponsor booths & poster session (continued)**

13:40 – 15:00 **session 7: parallel sessions on (A) fundamental & translational cancer research and (B) clinical & psychosocial/nursing cancer research**

session 7A: fundamental & translational research (location: Refter – ground floor)

- **13:40 introduction of the session**
- **13:45 international PriOMiC partner**  
**Prof. Maria Oliveira** (i3S Institute, Porto) – ‘Targeting macrophages at the tumor microenvironment: from 3D biomimetic models to immunomodulatory therapies’
- **14:10 selected abstract presentation**  
**Robin Boiy** (UGent, CRIG) –  
‘Rab27B-Melanophilin interaction steers breast cancer progression by removing cytosolic DNA to avoid Type-I interferon and innate immune response’
- **14:25 selected abstract presentation**  
**Elieen Hilgert** (UGent, CRIG) – ‘In vivo structure-function analysis supports a role for FANCD1 DNA helicase G4-unwinding activity in MYCN driven neuroblastoma formation: implications for novel drugging approaches’
- **14:40 selected abstract presentation**  
**Prof. Lars Vereecke** (VIB-UGent, CRIG) – ‘Study of microbial drivers in colorectal cancer development and therapy’

session 7B: clinical & psychosocial/nursing research (location: Vermeylen – first floor)

co-organized & chaired by UZ Gent Kankercentrum

- **13:40 introduction of the UZ Gent Kankercentrum – Prof. Gwen Sys** (coordinator)
- **13:50 invited speaker presentation**  
**Prof. Ann Van Hecke** (UGent, UCVV) & **Prof. Elke Rammant** (UGent) –  
introducing the ‘Research and Expertise group for Psychosocial Oncology and Survivorship (REPOS)’ in Ghent
- **14:00 invited speaker presentation**  
**Michiel Daem & Flore Herman** (Kankercentrum UZ Gent) - ‘Development and implementation of a cancer survivorship program’
- **14:15 invited speaker presentation**  
**Dr. Eva Pape** (Kankercentrum UZ Gent) – ‘Shared decision making in rectal cancer surgery: the way to go?’
- **14:30 selected abstract presentation**  
**Dr. Miet Vandemaële** (U(Z)Gent) – ‘Improving access to treatment and innovation: the call for a value-based assessment tool in radiotherapy’
- **14:45 selected abstract presentation**  
**Dr. Renée Bultijnck** (UGent) –  
‘Development of a healthcare provider screening tool to make patient-tailored referrals for exercise in cancer care, both during and after treatment’

- 15:00 – 15:30 **coffee break, sponsor booths & poster viewing**
- 15:30 – 16:50 **session 8: parallel sessions on (A) fundamental & translational research and (B) clinical & psychosocial/nursing research**

session 8A: fundamental & translational research (location: Refter – ground floor)

- **15:30 international PriOMiC partner**  
**Dr. Lars Feuerbach** (DKFZ) – ‘The use of Telomere-based biomarkers for the early detection and monitoring of cancer’
- **15:45 selected abstract presentation**  
**Dr. Jesse Demuytere** (U(Z)Gent, CRIG) – ‘Fibroblast heterogeneity in colorectal peritoneal metastasis’
- **16:00 selected abstract presentation**  
**Prof. Esther Hoste** (VIB-UGent, CRIG) – ‘Autophagy controls epidermal tumour formation and hair follicle stem cell activation’
- **16:15 selected abstract presentation**  
**Joshua Robert Goulding** (UGent, CRIG) – ‘Seeking synergistic partners for CDK12 inhibition and degradation in neuroblastoma’
- **16:30 selected abstract presentation**  
**Jolien Vanhooren** (UGent, CRIG) – ‘Deciphering the role of Nidogen-1 in pediatric acute myeloid leukemia’

session 8B: clinical & psychosocial/nursing research (location: Vermeylen – first floor)

co-organized & chaired by UZ Gent Kankercentrum

- **15:30 invited speaker presentation**  
**Brecht Gunst** (Stichting tegen Kanker) – ‘The Belgian Foundation against Cancer’s funding programs for psychosocial research and care projects’
- **15:45 invited speaker presentation**  
**Annelies Van den Eynden & Sofie Lauwers** (Kom op tegen Kanker) – ‘Financing psychosocial research and care projects by Kom op tegen Kanker’
- **16:00 invited speaker presentation**  
**Dr. Renée Bultijnck** (UGent) – ‘PROMs in advanced prostate cancer: what, which, why?’
- **16:15 invited speaker presentation**  
**Prof. Lore Lapeire & Nathalie Belpaeme** (Kankercentrum UZ Gent) – ‘Towards dedicated AYA (adolescents & young adults with cancer) care in Belgium’
- **16:30 selected abstract presentation**  
**Dr. Lise-Marie Kinnaer** (U(Z)Gent, UCVV) – ‘Experiences and needs of cancer patients with cardiovascular problems during systemic cancer treatment: preliminary results of an ongoing qualitative study’

17:00 – 17:30 **session 9 in memory of Prof. Pieter Van Vlierberghe  
& award for best paper in 2022 for a young CRIG researcher**

17:30 – 17:40 **closing remarks & awards for best presentations**

17:40 – 18:10 **session 10: ‘meet the international partners’** + opportunity to have a drink

*format:*

- *meet-the-expert session per international institute/partner that presented today – at separate round tables to allow face-to-face interaction and discussions in small groups (in the reception area, with opportunity to have a drink)*
- *participants can join the tables spontaneously, and visit several tables during the session to actively interact with the partners or to follow the ongoing discussions.*

18:10 – 18:40 **reception (continued)**